HPCAL1 (F5R3N) Rabbit Monoclonal Antibody #25638
- WB
- IP
- IF
Product Specifications
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 20 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunofluorescence (Immunocytochemistry) | 1:50 - 1:200 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
HPCAL1 has been implicated in both tumor-suppressing and tumor-promoting roles depending on the cancer type. In hepatocellular carcinoma (HCC), HPCAL1 acts as a tumor suppressor by stabilizing cell cycle regulators, suppressing mTOR signaling, and inhibiting lipid metabolism (3). Loss or downregulation of HPCAL1 has also been observed in HCC patients (4). Conversely, studies have shown that HPCAL1 promotes tumor progression in glioblastoma via activation of the Wnt/β-catenin pathway (5) and in non-small cell lung carcinoma via activation of lactate dehydrogenase A (LDHA) (6). Elevated HPCAL1 expression is also correlated with poor prognosis in both glioblastoma (7) and cholangiocarcinoma (8), further supporting its potential as a novel proto-oncogene.
- Spilker, C. et al. (2002) Biochim Biophys Acta 1600, 118-27.
- Chen, X. et al. (2023) Autophagy 19, 54-74.
- Chen, T. et al. (2022) Theranostics 12, 7450-7464.
- Zhang, Y. et al. (2016) Hepatology 63, 880-97.
- Zhang, D. et al. (2019) J Cell Mol Med 23, 3108-3117.
- Wang, X. et al. (2022) Cell Oncol (Dordr) 45, 179-191.
- Wang, L. et al. (2023) J Zhejiang Univ Sci B 24, 1053-1056.
- Ma, M. et al. (2023) Cancer Med 12, 824-836.
Alternate Names
BDR1; Calcium-binding protein BDR-1; hippocalcin like 1; hippocalcin-like 1; Hippocalcin-like protein 1; HLP2; HPCAL1; HPCL1; VILIP-3; Visinin-like protein 3
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.